Six Chinese Biotechs Bag $403m In Fresh Financing Rounds
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
You may also be interested in...
Two IPOs and 12 venture capital and private equity deals in China raised a combined $1bn in a hectic few weeks of October.
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
A concerted effort to mobilize the pharma industry, research organizations and state-backed healthcare venture capital firms is under way in Shanghai.